Monogenetic hypertension and pheochromocytoma.
Hypertension attributable to pheochromocytoma is a very attractive model for the elucidation of the pathogenesis of hypertension. Sixteen different point mutations in the RET proto-oncogene and 30 mutations in the Von Hippel-Lindau (VHL) tumor suppressor gene have been identified so far associated with expression of pheochromocytoma. Each of these mutations initiates either the syndrome of multiple endocrine neoplasia type 2 (MEN 2) (MEN 2A and MEN 2B) or the VHL disease. Certain mutations in both genes are associated with the presence of pheochromocytoma. In general, these pheochromocytomas produce catecholamines that result in hypertension. Therefore, analysis for germline mutations in these genes are of practical value, because susceptibility to these diseases can be predicted in as yet clinically unaffected relatives.
Neumann
H P
HP
Department of Nephrology and Hypertension, Albert-Ludwigs-University, Freibug, Germany.
Bender
B
B
Zäuner
I
I
Berger
D P
DP
Eng
C
C
Brauch
H
H
Zbar
B
B
D016147:Genes, Tumor Suppressor / Q000235:genetics; D018095:Germ-Line Mutation; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000235:genetics*; D018813:Multiple Endocrine Neoplasia Type 2a / Q000235:genetics; D010673:Pheochromocytoma / Q000150:complications / Q000235:genetics*; D017354:Point Mutation; D000090063:Proto-Oncogene Mas; D011519:Proto-Oncogenes / Q000235:genetics; D006623:von Hippel-Lindau Disease / Q000235:genetics